Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurrent Low Grade Gliomas (PNOC021)
Condition: Recurrent World Health Organization (WHO) Grade II Glioma Interventions: Drug: Everolimus; Drug: Trametinib Sponsors: University of California, San Francisco; Novartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation for Pediatric Brain Cancer Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Glioma | International Medicine & Public Health | Neurology | Pediatrics | Research | WHO